ICICI證券升級後，Sun Pharma股票週二超過3％

Sun Pharmaceutical Industries Limited的股票價格顯著上漲

Sun Pharmaceutical Industries Limited's stock price went up on Tuesday after ICICI Securities upgraded the company's rating from ‘Hold’ to ‘Buy’ and raised its price target.

Sun Pharmaceutical Industries Limited的股價在周二上漲，因為ICICI Securities將公司的評級從“持有”提高到“買入”，並提高了其價格目標。

The new report from the brokerage firm highlights strong growth potential and a recent strategic acquisition by Sun Pharma, which specializes in making drugs.

經紀公司的新報告強調了強大的增長潛力，以及Sun Pharma的最新戰略收購，專門從事製造藥物。

Early in trading on Tuesday, Sun Pharma's shares went up more than 3% to reach Rs 1,655.95 apiece. This follows a correction of almost 10% over the last two months.

在周二交易的早期，Sun Pharma的股票上漲了3％以上，每股達到1,655.95盧比。在過去的兩個月中，這是幾乎10％的糾正。

Later in the day, the shares were trading at Rs 1,634.85 apiece, up 1.4%.

當天晚些時候，股票的交易價格為1,634.85盧比，增長了1.4％。

The new price target from ICICI Securities is Rs 1,895, which is based on 31x the brokerage firm's estimate for FY 27 earnings per share. Before, the price target was based on a 32x multiple of the company's estimated FY 26 earnings per share.

ICICI證券的新價格目標是1,895盧比，基於31倍經紀公司對每股27財年收益的估算。以前，目標目標是基於公司估計每股26財年收益的32倍倍數。

The report from the brokerage firm also says, "We prefer Sun Pharma over peers due to its specialty focus, strong R&D productivity, and improving balance sheet."

經紀公司的報告還說：“由於其專業重點，強大的研發生產力和提高資產負債表，我們更喜歡Sun Pharma而不是同行。”

Other major brokerage firms are also optimistic about Sun Pharma. Both Motilal Oswal and HDFC Securities keep their 'Buy' ratings and price target of Rs 1,970, while Incred maintains a 'Hold' rating with a price target of Rs 1,900.

其他主要經紀公司也對Sun Pharma感到樂觀。 Motilal Oswal和HDFC證券都將其“買入”評級和目標目標保持在1,970盧比，而Inge則保持了“持有”評級，目標價為1,900盧比。

This positive outlook from several analysts suggests that everyone agrees that Sun Pharma's recent strategic moves could be important for investors and lead to a good return on investment.

幾位分析師的這種積極的前景表明，每個人都同意Sun Pharma最近的戰略舉動對投資者可能很重要，並帶來了良好的投資回報。

Sun Pharma is expanding its oncology presence

Sun Pharma正在擴大其腫瘤學的存在

One of the main reasons for the stock's recent momentum is the acquisition of Checkpoint Therapeutics, a biotech company listed on Nasdaq that is in the early stages of development and focuses on oncology.

股票最近勢頭的主要原因之一是收購Checkpoint Therapeutics，這是一家在納斯達克上列出的生物技術公司，該公司處於發展的早期階段，專注於腫瘤學。

The acquisition, which is valued at $355 million, is part of Sun Pharma's long-term plan to become stronger in the oncology and immunotherapy markets.

這次收購價值為3.55億美元，是Sun Pharma長期計劃在腫瘤學和免疫療法市場上變得更強大的計劃的一部分。

"The transaction is expected to close in the second half of 2025 and is subject to regulatory approvals and other standard closing conditions," the statement said.

聲明說：“預計該交易將在2025年下半年結束，並受到監管部門的批准和其他標準關閉條件。”

Checkpoint is best known for making anti-PD-L1 (Programmed Death Ligand-1) inhibitors, which are used to treat several types of cancer with fewer side effects than traditional chemotherapy.

檢查點最著名的是製造抗PD-L1（編程死亡配體1）抑製劑，該抑製劑用於治療幾種類型的癌症，其副作用少於傳統化學療法。

This move puts Sun Pharma in the lively space of immuno-oncology and adds to its already strong portfolio of onco-dermatology products.

此舉使Sun Pharma成為免疫腫瘤學生動的空間，並增加了其本已強大的Onco-Dermatology產品組合。

The acquisition also fits with Sun Pharma's strategy of making more specialty products in areas of treatment that are growing quickly. Earlier in 2023, Sun Pharma bought Concert Pharmaceuticals for $576 million, which increased its portfolio of dermatology and autoimmune treatments.

此次收購還符合Sun Pharma在迅速增長的治療領域製造更多專業產品的策略。 2023年早些時候，Sun Pharma以5.76億美元的價格購買了Concert Pharmaceuticals，這增加了其皮膚病學和自身免疫性治療的組合。

"This acquisition is a part of Sun Pharma's strategy to expand its specialty pharmaceutical business, especially in oncology and dermatology, which is a key area of focus for the company," the statement said.

聲明說：“此次收購是Sun Pharma擴大其專業製藥業務的戰略的一部分，尤其是在腫瘤學和皮膚病學領域，這是該公司的關鍵領域。”

Recently, Sun Pharma has been quickly expanding its specialty pharmaceutical business and making a series of strategic investments to strengthen its pipeline.

最近，Sun Pharma一直在迅速擴大其專業製藥業務，並進行一系列戰略投資以加強管道。

In 2024, the company also made a deal with Philogen to get the global exclusive commercialization, licensing, and supply rights for FIBROMUN, a promising oncology product. This move shows that it is committed to becoming a leader in specialty pharmaceuticals, especially for cancer treatment.

2024年，該公司還與Philogen達成了一項協議，以獲得全球獨家商業化，許可和供應權，以獲得有前途的腫瘤產品Fibromun。此舉表明，它致力於成為專業藥品的領導者，尤其是在癌症治療方面。

As the global immuno-oncology sector is expected to grow quickly over the next ten years thanks to advances in targeted therapies and biologics, Sun Pharma's latest acquisition could help it stand out in a competitive market.

由於有針對性的療法和生物製劑的進步，預計全球免疫腫瘤部門將在未來十年內迅速增長，Sun Pharma的最新收購可以幫助它在競爭激烈的市場中脫穎而出。

The company is also making a big effort to expand into China, which is the world's second-largest pharmaceutical market.

該公司還付出了巨大的努力，以擴展到中國，這是世界第二大製藥市場。

Earlier this year, it was said that Sun Pharma would apply for approval to sell two of its specialty drugs in China, which shows that it wants to expand into new geographical markets.

今年早些時候，據說Sun Pharma將申請批准在中國出售其兩種特種藥物，這表明它希望擴展到新的地理市場。

With strong financial backing and a clear vision for the future, Sun Pharma seems to be well-suited to take advantage of new opportunities in the global pharmaceutical market as it expands its specialty business, and market researchers will be paying close attention to see how it does.

憑藉強大的財務支持和對未來的清晰願景，Sun Pharma似乎非常適合在全球製藥市場中利用新的機會，因為它擴大了其專業業務，並且市場研究人員將密切關注以了解它的表現。